September 9, 2026
Bonus Content: Novartis Lost $30 Billion in Two Failures. What Was at Stake.
The $1.1 Trillion Question Hanging Over Your Retirement
Why what happens in Tokyo may not stay in Tokyo
Dear Reader,
This summer, something happened in the currency markets that received almost no airtime.
In late July, the U.S. Treasury and the Bank of Japan took coordinated action to steady the yen. Two of the most powerful financial institutions on earth, moving together, to hold up a major world currency.
Most Americans shrugged. Japan’s problem, right?
Not quite. Because according to U.S. Treasury data, Japan holds more than $1.1 trillion of America’s debt.
That makes Tokyo one of Washington’s biggest creditors. When you owe someone a trillion dollars, their problems have a way of becoming your problems.
Here is the chain reaction analysts quietly worry about.
Japan’s own borrowing costs have climbed to levels its bond market has not seen in decades. If pressure on the yen returns and Tokyo ever needs cash to defend its own currency, one of its largest piggy banks is that mountain of U.S. Treasuries.
And if a creditor that size ever becomes a seller, the question the market has to answer is simple.
Who buys? And at what price?
Higher yields. More expensive debt. More pressure on the dollar your IRA, 401(k), TSP, or 403(b) is built on. Each problem feeding the next. Some analysts have started calling it a doom loop.
Nobody can say if or when that loop tightens. That is exactly the point. The risks that hurt savers most are the ones that build quietly overseas while everyone watches the headlines at home.
Which may explain why the world’s central banks, including buyers across Asia, have been adding gold to their reserves at a historic pace, according to World Gold Council reporting.
Gold is nobody’s debt. It has no issuer, no creditor, and no currency to defend. It has historically served as a store of value precisely when confidence in paper systems is tested.
That is why America’s Gold Company created a FREE Precious Metals Retirement Guide for everyday Americans who want to understand their options before the next quiet story becomes a loud one.
Inside your free guide, you will discover:
- ✔ Why foreign holders of U.S. debt matter to the savings you hold at home.
- ✔ How gold has historically responded during periods of currency stress and shaken confidence.
- ✔ How a Gold IRA generally works, and how you may be eligible to move a portion of an existing IRA, 401(k), TSP, or 403(b) into physical metals without triggering taxes or penalties.
- ✔ How physical metals can help diversify savings outside the paper system.
- ✔ A simple, conservative way to get started.
Request Your FREE Precious Metals Retirement Guide Here
Or speak with a precious metals specialist today at 1-888-691-8238.
To your financial security,
America’s Gold Company
P.S. The yen needed a lifeline this summer, and the country that got it holds over $1.1 trillion of our debt. You cannot control what Tokyo does next. You can control whether your savings depend entirely on paper when it happens. Get your free guide here.
Novartis Lost $30 Billion in Two Failures. What Was at Stake.
The Novartis story this week is not, at its core, about myotonic dystrophy or antibody-oligonucleotide conjugates. It is about how markets value the future relative to the present, and what happens when that future gets marked to zero. That same arithmetic governs every sector where today’s cash flows are modest and tomorrow’s discovery is the entire thesis, including gold mining.
What’s Driving the Market
On Tuesday, Novartis reported that its Phase III HARBOR study of del-desiran, a muscle-wasting disorder drug acquired in last year’s $12 billion Avidity Biosciences takeover, failed to show statistically significant improvement over placebo on its primary endpoint of video hand opening time. The global HARBOR study enrolled approximately 150 patients with the progressive muscle-wasting disease and ran for 54 weeks. The pharma’s share price was trading down 12.5% in pre-market at $139.98 from a Friday closing price of $159.99.
It was the second major readout failure in days. The del-desiran result came just days after Novartis said its pelacarsen drug failed to reduce the risk of cardiovascular events in a late-stage trial, and a week after announcing it had paused eight clinical trials of an experimental cell therapy, rap-cel, after three patients died. The run of flops leaves Novartis with one win and two failures from a rapid-fire sequence of key clinical readouts.
The twin failures wiped around $29.6 billion off Novartis’s market value. That figure tells you something precise: it is the market’s real-time estimate of what those two drugs were worth inside the stock price before Tuesday morning.
The Investment Opportunity: A Framework
Before the HARBOR readout, analysts had Novartis trading at roughly 16 times forward earnings, a premium to large-cap pharma peers. Some analysts had warned that much of the potential upside from the trial results was already reflected in that sector-leading valuation, with Jefferies analyst Michael Leuchten noting: “At 16 times, you do need those growth levers to come through.”
Analysts had estimated the three pipeline drugs together represented more than $10 billion in peak annual sales potential, enough to balance expected patent losses for top-sellers Cosentyx and Kisqali around the turn of the decade. Barclays alone had modeled $3.1 billion in peak annual del-desiran sales and assigned the drug a 60% probability of success after Phase II data looked promising. Two of those three drugs have now failed.
This is the pipeline optionality problem made visible. CEO Vas Narasimhan has focused on rebuilding Novartis’s pipeline after spinning off its generics and consumer businesses while confronting what he has called the company’s steepest patent cliff in decades. Jefferies said the company’s 5% to 6% annual sales growth target through 2030 will likely be seen as unattainable without further mergers and acquisitions, and noted that management’s ability to do large deals is now itself under scrutiny.
The same math applies to gold mining. When a major producer trades at 20 times cash flow during an exploration cycle, a significant portion of that premium reflects assets that do not yet produce an ounce. A failed drill program or resource write-down can reset the stock 15% in a session, not because today’s mine stopped working, but because the market was paying for tomorrow’s mine that no longer exists. Novartis just illustrated that dynamic with $30 billion of precision.
Risks to Monitor
Novartis is still advancing del-zota in Duchenne muscular dystrophy, having filed for accelerated approval and received FDA priority review designation. The company is also planning FDA discussions on del-brax in facioscapulohumeral muscular dystrophy based on positive Phase 1/2 biomarker data. Two of the three Avidity assets remain in play. Whether that justifies any part of the $12 billion acquisition price is now the central question for NVS shareholders.
The collateral damage extended well beyond Novartis. Dyne Therapeutics and Sarepta Therapeutics, which are developing treatments for muscular dystrophy, fell 27% and 11% respectively in early trading. The failure was particularly impactful for Sarepta because its SRP-1003 is also an siRNA targeting DMPK RNA in DM1, though it uses a different delivery mechanism than del-desiran. Mizuho maintained its Sarepta rating, arguing the mechanism distinction matters, but the market sold first and asked mechanistic questions later.
As H.C. Wainwright analyst Ananda Ghosh framed it: “The big question is whether it’s an endpoint miss or whether mechanism has completely failed or not.” That distinction will determine whether competing programs in DM1 survive or follow del-desiran into the file drawer.
Bottom Line
Two failures inside five sessions taught Novartis investors something they should have already known: a stock price with a 16-times multiple and a patent cliff cannot afford to be wrong twice in a week on the drugs that were supposed to fill the gap. The $29.6 billion erased was not a surprise reaction to bad science. It was the market collecting on a bet it had already priced in at high confidence.
For investors in any capital-intensive industry where future discovery drives valuation, that is the framework worth carrying forward. The question is never just whether the stock is cheap today. It is what percentage of today’s price reflects assets that do not yet exist, and what happens to that percentage when one data point removes them.